Cargando…

Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease

BACKGROUND: Secondary hyperparathyroidism (sHPT) develops frequently in patients with chronic kidney disease (CKD). However, the burden and long-term impact of sHPT on the risk of adverse health outcomes are not well studied. METHODS: We evaluated all adults receiving nephrologist care in Stockholm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yang, Evans, Marie, Soro, Marco, Barany, Peter, Carrero, Juan Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483675/ https://www.ncbi.nlm.nih.gov/pubmed/34603697 http://dx.doi.org/10.1093/ckj/sfab006

Ejemplares similares

Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism
por: Evans, Marie, et al.
Publicado: (2018)

Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study
por: Xu, Yang, et al.
Publicado: (2021)

Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis
por: Evans, Marie, et al.
Publicado: (2020)

Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study
por: Laureati, Paola, et al.
Publicado: (2019)

Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment
por: Joy, Melanie S., et al.
Publicado: (2007)

Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project
por: Gasparini, Alessandro, et al.
Publicado: (2019)

Secondary hyperparathyroidism among Nigerians with chronic kidney disease
por: Gimba, Zumnan M, et al.
Publicado: (2018)

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)

Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease
por: Trevisan, Marco, et al.
Publicado: (2021)

Real-World Analysis of Outcomes and Economic Burden in Patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a Sample of the Italian Population
por: Barbuto, Simona, et al.
Publicado: (2023)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease
por: Naveh-Many, Tally, et al.
Publicado: (2020)

Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREAtinine Measurement project
por: Runesson, Björn, et al.
Publicado: (2019)

Association of Secondary Hyperparathyroidism with Hemoglobin Level in Patients with Chronic Kidney Disease
por: Chutia, Happy, et al.
Publicado: (2013)

Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2020)

Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective
por: Chandran, Manju, et al.
Publicado: (2019)

Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease
por: Lin, Li-Ping, et al.
Publicado: (2023)

Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital
por: Manjarres, Luis, et al.
Publicado: (2016)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
por: Friedl, Claudia, et al.
Publicado: (2017)

Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study
por: Xu, Hong, et al.
Publicado: (2021)

Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care
por: Bosi, Alessandro, et al.
Publicado: (2021)

Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels
por: Zhao, Yu, et al.
Publicado: (2016)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease
por: Strugnell, Stephen A., et al.
Publicado: (2023)

Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction
por: Szummer, Karolina, et al.
Publicado: (2017)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4
por: Dheerendra, P. C., et al.
Publicado: (2013)

The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS
por: Cannata-Andía, Jorge B., et al.
Publicado: (2008)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Outcome of Total Parathyroidectomy and Autotransplantation as Treatment of Secondary and Tertiary Hyperparathyroidism in Children and Adults
por: Kievit, A. J., et al.
Publicado: (2010)

Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis
por: Davies, Evan W., et al.
Publicado: (2015)

Is Chronic Varicocele a Risk Factor for Secondary Hyperparathyroidism?
por: Cannarella, Rossella, et al.
Publicado: (2022)

Albuminuria as a Predictor of Cardiovascular Outcomes in Patients With Acute Myocardial Infarction
por: Mok, Yejin, et al.
Publicado: (2019)

Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm CREAtinine Measurement project
por: Su, Guobin, et al.
Publicado: (2019)

Association between incident depression and clinical outcomes in patients with chronic kidney disease
por: Zhu, Nanbo, et al.
Publicado: (2023)

Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project
por: Alkas, Jim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vu4anshf7armu458vmh20q6vka